Literature DB >> 32266703

Why Only Test Symptomatic Patients? Consider Random Screening for COVID-19.

William V Padula1,2.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32266703      PMCID: PMC7138654          DOI: 10.1007/s40258-020-00579-4

Source DB:  PubMed          Journal:  Appl Health Econ Health Policy        ISSN: 1175-5652            Impact factor:   2.561


× No keyword cloud information.
The world is at war with the coronavirus disease 2019 (COVID-19) pandemic. With many places still facing a drastic shortage of testing resources, what is the best way to deploy these scarce tests? In the United States (US), the Center for Disease Control and Prevention (CDC) implemented strict criteria that a patient needed to satisfy to qualify for testing, including (1) physical symptoms of COVID-19; (2) recent travel to areas of an outbreak; and (3) direct contact with a person who tested positive for COVID-19 [1]. Additional criteria to narrow allocation included individuals over age 65 years, frontline healthcare workers, and hospitalized patients. These circumstances are somewhat unique to the US, since other nations have not expressed the same degree of COVID-19 test kit shortages. The United Kingdom (UK) has conducted over 90,000 tests, while still adhering to strict guidelines for testing, including hospital admission and pneumonia; acute respiratory distress syndrome; or influenza like symptoms [2]. By contrast, Canada has conducted over 50,000 tests nationwide under a fairly flexible policy that any patient presenting with coronavirus symptoms is eligible [3]. Wherever the cases may present, testing patients who satisfy some of these criteria is more likely to generate positive test results than testing those who do not exhibit one of these conditions. Yet, the instinct that we should be concentrating testing on patients who exhibit salient markers of the disease may be suboptimal in stunting the transmission rate. Tactics that the US deployed during World War II provide an important history lesson on how US public health officials should be allocating testing. Back then, the US Army Air Forces brass were concerned with optimally placing armor on bomber planes, with the objective of maximizing the rate at which their pilots survived battle and returned home. Bombers returning from missions often had multitudes of scattered bullet holes. The army’s initial instinct was to allocate scarce armor on those areas of the plane that were hit hardest. By focusing on the salient and hardest hit areas of the surviving planes, the army was systematically neglecting areas of the plane that when shot at were most vulnerable to crashing (e.g., the engines and cockpit). Abraham Wald, the Hungarian mathematician who defected to the US at the war’s outbreak, recommended an altered strategy to improve aircraft survivability. By studying the distribution of bullet holes throughout multiple aircraft that returned, he deducted that planes needed continued protection of the engines and cockpit to continue returning home, so armor were placed systematically on these areas of all aircraft despite the observable data of bullet holes in the bomber fuselages [4]. In the context of a pandemic during which many people may be infected but asymptomatic, a similar logic suggests that allocating scarce diagnostic resources towards those who do not exhibit warning signs of infection is crucial. If asymptomatic patients are less likely to follow public health guidelines such as social distancing or self-isolation compared to patients who do exhibit symptoms, then providing information to asymptomatic patients that they are infected is a critical step in mitigating disease transmission. During the brief amount of time that the US has been able to study the COVID-19 outbreak, there has been substantial evidence to support the belief that many of the infected population are asymptomatic. For instance, according to Nishiura and colleagues, the ill-fated Diamond Princess cruise ship had an asymptomatic COVID-19 infection prevalence of 30.8% in an adult population [5]. The American Academy of Pediatrics currently reports that about 4% of children are asymptomatic and 51% have only mild symptoms [6]. These data imply that while symptomatic patients are worth screening to properly manage them, the US should consider randomizing testing in the general population or potentially shifting test resources away from symptomatic patients and towards those who are least likely to consider themselves infected. In terms of information theory, one objective of a test is to maximize the “surprise” that a person experiences when receiving a test result [7]. A test result that is not surprising and simply confirms a prior belief has limited value, particularly when tests are scarce. On the other hand, if a person has a strong belief that they are not infected, but then receives a positive test result, they will then likely exhibit a larger change in their behavior compared to a person who simply received confirmatory results. In addition, increasing the proportion of surprising test results will also be valuable to public health officials in painting a more accurate picture of the spread of the disease. Given these considerations, where do we go from here? US public health officials should make a concerted effort to conserve the supply of COVID-19 test kits [8], but specifically for random sampling in the community. Areas of the US geography that appear to be less impacted by the disease (e.g., West Virginia, Upper Midwest states, Mountain-West states), despite current data, could become problematic epicenters in the days and weeks to come given that these areas are unlikely to experience the same drastic behavioral shifts that locations like California and New York have adopted. Practical concerns will persist with this recommendation, such as distributing test kits to less population-dense areas where disease spread is still common (e.g., suburban areas) and convincing patients presenting with mild or no coronavirus symptoms to volunteer for testing. One caveat to close with is that this recommendation for random testing depends on the assumption that no treatment is currently available. Without treatment, knowing how to manage population health through primary and preventive care is our strongest weapon. However, if a treatment were to evolve in the coming months, then primarily testing symptomatic patients would become a much more valuable strategy in order to effectively allocate treatment resources to the infected for promoting disease recovery [9].
  3 in total

1.  Conserving Supply of Personal Protective Equipment-A Call for Ideas.

Authors:  Howard Bauchner; Phil B Fontanarosa; Edward H Livingston
Journal:  JAMA       Date:  2020-03-20       Impact factor: 56.272

2.  Audio Interview: New Research on Possible Treatments for Covid-19.

Authors:  Eric J Rubin; Lindsey R Baden; Stephen Morrissey
Journal:  N Engl J Med       Date:  2020-03-19       Impact factor: 91.245

3.  Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19).

Authors:  Hiroshi Nishiura; Tetsuro Kobayashi; Takeshi Miyama; Ayako Suzuki; Sung-Mok Jung; Katsuma Hayashi; Ryo Kinoshita; Yichi Yang; Baoyin Yuan; Andrei R Akhmetzhanov; Natalie M Linton
Journal:  Int J Infect Dis       Date:  2020-03-14       Impact factor: 3.623

  3 in total
  10 in total

1.  Evaluation of Allocation Schemes of COVID-19 Testing Resources in a Community-Based Door-to-Door Testing Program.

Authors:  Ben Chugg; Lisa Lu; Derek Ouyang; Benjamin Anderson; Raymond Ha; Alexis D'Agostino; Anandi Sujeer; Sarah L Rudman; Analilia Garcia; Daniel E Ho
Journal:  JAMA Health Forum       Date:  2021-08-27

2.  Robust Testing in Outpatient Settings to Explore COVID-19 Epidemiology: Disparities in Race/Ethnicity and Age, Salt Lake County, Utah, 2020.

Authors:  Sharia M Ahmed; Rashmee U Shah; Valerie Fernandez; Sara Grineski; Benjamin Brintz; Matthew H Samore; Matthew J Ferrari; Daniel T Leung; Lindsay T Keegan
Journal:  Public Health Rep       Date:  2021-02-04       Impact factor: 2.792

3.  Smart testing and selective quarantine for the control of epidemics.

Authors:  Matthias Pezzutto; Nicolás Bono Rosselló; Luca Schenato; Emanuele Garone
Journal:  Annu Rev Control       Date:  2021-03-26       Impact factor: 6.091

Review 4.  Humoral immunological kinetics of severe acute respiratory syndrome coronavirus 2 infection and diagnostic performance of serological assays for coronavirus disease 2019: an analysis of global reports.

Authors:  Anthony Uchenna Emeribe; Idris Nasir Abdullahi; Halima Ali Shuwa; Leonard Uzairue; Sanusi Musa; Abubakar Umar Anka; Hafeez Aderinsayo Adekola; Zakariyya Muhammad Bello; Lawal Dahiru Rogo; Dorcas Aliyu; Shamsuddeen Haruna; Yahaya Usman; Habiba Yahaya Muhammad; Abubakar Muhammad Gwarzo; Justin Onyebuchi Nwofe; Hassan Musa Chiwar; Chukwudi Crescent Okwume; Olawale Sunday Animasaun; Samuel Ayobami Fasogbon; Lawal Olayemi; Christopher Ogar; Chinenye Helen Emeribe; Peter Elisha Ghamba; Luqman O Awoniyi; Bolanle O P Musa
Journal:  Int Health       Date:  2022-01-19       Impact factor: 2.473

5.  Comparison of high-frequency in-pipe SARS-CoV-2 wastewater-based surveillance to concurrent COVID-19 random clinical testing on a public U.S. university campus.

Authors:  Jillian Wright; Erin M Driver; Devin A Bowes; Bridger Johnston; Rolf U Halden
Journal:  Sci Total Environ       Date:  2022-01-06       Impact factor: 10.753

6.  Examining the association between reported COVID-19 symptoms and testing for COVID-19 in Canada: a cross-sectional survey.

Authors:  Roland Pongou; Bright Opoku Ahinkorah; Marie Christelle Mabeu; Arunika Agarwal; Stephanie Maltais; Sanni Yaya
Journal:  BMJ Open       Date:  2022-03-04       Impact factor: 2.692

7.  Response of US psychiatric programs to the COVID-19 pandemic and the impact on trainees.

Authors:  Tyler Durns; Thomas Gethin-Jones; Eric Monson; Jennifer O'Donohoe
Journal:  BMC Med Educ       Date:  2022-04-01       Impact factor: 2.463

8.  Seroprevalence of SARS-CoV-2 antibodies among blood donors in Québec: an update from a serial cross-sectional study.

Authors:  Antoine Lewin; Gaston De Serres; Yves Grégoire; Josée Perreault; Mathieu Drouin; Marie-Josée Fournier; Tony Tremblay; Julie Beaudoin; Amélie Boivin; Guillaume Goyette; Andrés Finzi; Renée Bazin; Marc Germain; Gilles Delage; Christian Renaud
Journal:  Can J Public Health       Date:  2022-04-05

9.  Course of the first month of the COVID 19 outbreak in the New York State counties.

Authors:  Anca Rǎdulescu
Journal:  PLoS One       Date:  2020-09-02       Impact factor: 3.240

10.  Ratio of asymptomatic COVID-19 cases among ascertained SARS-CoV-2 infections in different regions and population groups in 2020: a systematic review and meta-analysis including 130 123 infections from 241 studies.

Authors:  Xiao Chen; Ziyue Huang; Jingxuan Wang; Shi Zhao; Martin Chi-Sang Wong; Ka Chun Chong; Daihai He; Jinhui Li
Journal:  BMJ Open       Date:  2021-12-07       Impact factor: 3.006

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.